Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily probiotic soothe baby eczema?

NCT ID NCT05286047

Symptom relief Sponsor: Glac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a daily probiotic called Bifidobacterium longum CCFM1029 can reduce eczema symptoms in infants aged 3 months to 3 years. One hundred children with atopic dermatitis were split into two groups: one received the probiotic and the other a placebo for 3 months. Researchers tracked changes in eczema severity and gut bacteria to see if the probiotic helps calm inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bifidobacterium longum CCFM1029 (a probiotic dietary supplement)
What this could lead to
If it works, this could point toward a simple, safe probiotic option to help manage eczema in infants.
What could go wrong
This is a small, early-stage trial with only 100 participants. The effect may be modest or not better than placebo, and results may not apply to all infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Sep 2022

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 months to 3 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects were between 3 months and 3 years old. * For patients diagnosed with atopic dermatitis by a professional physician and the EASI score is greater than 5, the type and frequency of drugs used during the experiment should be recorded. * The subject's parents agree to join the trial and sign the informed consent form. Exclusion Criteria: * The patient who has a history of allergic reactions, or the use of other highly sensitive or contraindicated drugs (allergy to antibiotics or antipyretics). * The patient who has taken oral immunosuppressants and systemic steroids within the past 2 weeks. * The patient who has consumed probiotic-related products (including drops, lozenges, capsules, powder or yogurt) within the past 1 month. * The patient who has participated in other clinical studies within the past 1 month. * The patient who has received immunotherapy within the past 1 year. * The patient who suffering from major diseases (with a IC card for severe illness), congenital diseases. * The patient who is not suitable to participate in the trial as assessed by the professional physician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Glac Biotech Co., Ltd.

    Tainan, 74442, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.